CLEAR CELL CRIBRIFORM HYPERPLASIA OF THE PROSTATE - IMMUNOHISTOCHEMICAL AND DNA FLOW CYTOMETRIC STUDY

被引:22
作者
FRAUENHOFFER, EE [1 ]
RO, JY [1 ]
ELNAGGAR, AK [1 ]
ORDONEZ, NG [1 ]
AYALA, AG [1 ]
机构
[1] UNIV TEXAS,MD ANDERSON CANCER CTR,DEPT PATHOL,BOX 85,1515 HOLCOMBE BLVD,HOUSTON,TX 77030
关键词
CLEAR CELL CRIBRIFORM HYPERPLASIA; PROSTATIC HYPERPLASIA; BASAL CELL KERATIN; DNA ANALYSIS;
D O I
10.1093/ajcp/95.4.446
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
Clear cell cribriform hyperplasia (CCCH) of the prostate is an unusual form of benign prostatic hyperplasia characterized by a nodular proliferation of clear cells with small, uniform nuclei. The authors studied 15 cases of CCCH by immunohistochemistry and 13 of them by DNA flow cytometry to establish the immunohistochemical and DNA profile of this lesion. Patients ranged in age from 58 to 88 years (mean, 68 years). Follow-up of a mean of 22 months showed all patients alive with no evidence of malignant prostatic disease. All 13 CCCHs showed diploid DNA content; in contrast, among 4 papillary/cribriform carcinomas of the prostate used for comparison, 3 were aneuploid and 1 was diploid. A basal cell layer was demonstrated in all 15 CCCHs by the use of the 34-beta-E12 anti-high-molecular-weight keratin antibody (EAB-903) that reacts with the basal cells but not with the acinar cells of the prostate. A continuous basal cell cell epithelium, the well-defined nodular configuration, the presence of a basal cell layer demonstrable by immunocytochemistry, and the lack of aneuploidy as determined by DNA flow cytometry together lend support to the concept that CCCH is a benign lesion.
引用
收藏
页码:446 / 453
页数:8
相关论文
共 27 条
[1]   CLEAR CELL CRIBRIFORM HYPERPLASIA OF PROSTATE - REPORT OF 10 CASES [J].
AYALA, AG ;
SRIGLEY, JR ;
RO, JY ;
ABDULKARIM, FW ;
JOHNSON, DE .
AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 1986, 10 (10) :665-671
[2]  
AYALA AG, 1987, AM J SURG PATHOL, V11, P489, DOI 10.1097/00000478-198706000-00014
[3]  
BOSTWICK DG, 1987, CANCER, V59, P788, DOI 10.1002/1097-0142(19870215)59:4<788::AID-CNCR2820590421>3.0.CO
[4]  
2-I
[5]  
BOSTWICK DG, 1988, SEMIN DIAGN PATHOL, V5, P240
[6]  
BRAWER MK, 1985, CANCER RES, V45, P3663
[7]  
BRAWER MK, 1989, CANCER, V63, P454, DOI 10.1002/1097-0142(19890201)63:3<454::AID-CNCR2820630311>3.0.CO
[8]  
2-E
[9]  
BRAWN PN, 1982, CANCER, V49, P525, DOI 10.1002/1097-0142(19820201)49:3<525::AID-CNCR2820490321>3.0.CO
[10]  
2-M